Autophagy and Apoptotic Crosstalk: Mechanism of Therapeutic Resistance in HER2-Positive Breast Cancer

被引:40
作者
Zambrano, Joelle [1 ]
Yeh, Elizabeth S. [1 ]
机构
[1] Med Univ S Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, Charleston, SC 29425 USA
来源
BREAST CANCER-BASIC AND CLINICAL RESEARCH | 2016年 / 10卷
关键词
HER2; breast cancer; resistance; autophagy; apoptosis; trastuzumab; lapatinib;
D O I
10.4137/BCBCR.S32791
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
While breast cancer patients benefit from the use of HER2 inhibitors, many fail therapy and become resistant to treatment, indicating a critical need to prevent treatment failure. A number of studies have emerged that highlight the catabolic process of autophagy in breast cancer as a mechanism of resistance to chemotherapy and targeted inhibitors. Furthermore, recent research has begun to dissect how autophagy signaling crosstalks with apoptotic signaling. Thus, a possible strategy in fighting resistance is to couple targeting of apoptotic and autophagy signaling pathways. In this review, we discuss how cellular response by autophagy circumvents cell death to promote resistance of breast cancers to HER2 inhibitors, as well as the potential avenues of therapeutic intervention.
引用
收藏
页码:13 / 23
页数:11
相关论文
共 99 条
  • [21] Resistance to HER2-directed antibodies and tyrosine kinase inhibitors
    Garrett, Joan T.
    Arteaga, Carlos L.
    [J]. CANCER BIOLOGY & THERAPY, 2011, 11 (09) : 793 - 800
  • [22] Gayle SS, 2012, ANTI-CANCER AGENT ME, V12, P151
  • [23] Converting Cancer Therapies into Cures: Lessons from Infectious Diseases
    Glickman, Michael S.
    Sawyers, Charles L.
    [J]. CELL, 2012, 148 (06) : 1089 - 1098
  • [24] DAP-kinase is a mediator of endoplasmic reticulum stress-induced caspase activation and autophagic cell death
    Gozuacik, D.
    Bialik, S.
    Raveh, T.
    Mitou, G.
    Shohat, G.
    Sabanay, H.
    Mizushima, N.
    Yoshimori, T.
    Kimchi, A.
    [J]. CELL DEATH AND DIFFERENTIATION, 2008, 15 (12) : 1875 - 1886
  • [25] Targeting AMPK: A new therapeutic opportunity in breast cancer
    Hadad, Sirwan M.
    Fleming, Stewart
    Thompson, Alastair M.
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2008, 67 (01) : 1 - 7
  • [26] Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
    Hudis, Clifford A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (01) : 39 - 51
  • [27] Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer
    Hurvitz, Sara A.
    Dirix, Luc
    Kocsis, Judit
    Bianchi, Giulia V.
    Lu, Janice
    Vinholes, Jeferson
    Guardino, Ellie
    Song, Chunyan
    Tong, Barbara
    Ng, Vivian
    Chu, Yu-Waye
    Perez, Edith A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (09) : 1157 - 1163
  • [28] MicroRNA-7 Inhibits Multiple Oncogenic Pathways to Suppress HER2Δ16 Mediated Breast Tumorigenesis and Reverse Trastuzumab Resistance
    Huynh, Felicia C.
    Jones, Frank E.
    [J]. PLOS ONE, 2014, 9 (12):
  • [29] Aberrant Splicing of Estrogen Receptor, HER2, and CD44 Genes in Breast Cancer
    Inoue, Kazushi
    Fry, Elizabeth A.
    [J]. GENETICS & EPIGENETICS, 2015, 7 : 19 - 32
  • [30] Jain K, 2013, AM J CANCER RES, V3, P251